The effects of other drugs like bortezomib, thalidomide, and newer agents such as carfilzomib, isatuximab, pomalidomide, CD38+ monoclonal antibodies, and selinexor, which are widely employed in patients suffering from relapsed and refractory MM, on hematopoietic stem cell mobilization are also unclear, particularly as there are few studies related to ASCT. The gene discussed is CD38; the disease is Miyoshi myopathy.